Patent · US Active

Use of TNF-alpha inhibitor for treatment of psoriasis

US8906373B2 · kind B2 · utility

15Cited by

65References

9Claims

0Family size

Assignee

AbbVie Biotechnology Ltd. · BM

Inventors

Subhashis Banerjee · Hamden, US
Rebecca S. Hoffman · Wilmette, US
Mark Weinberg · Northbrook, US
Lori K. Taylor · Boston, US
Clive E. Spiegler · Skillman, US
Daniel Edward Tracey · Harvard, US
Elliot K. Chartash · Dover, US
William T. Barchuk · San Diego, US
Philip Yan · Vernon Hills, US
Anwar Murtaza · North Grafton, US
Jochen G. Salfeld · North Grafton, US
Steven A. Fischkoff · Short Hills, US
George R. Granneman · Lindenhurst, US

Key dates

Filing date	Apr 30, 2014
Grant date	Dec 9, 2014
Priority date	—
Expiry date	Apr 30, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.